The NCE Standing Selection Committee is composed of international calibre experts with broad, multidisciplinary and multisectoral expertise, representing the domains of the three federal granting agencies, as well as the diversity of current government priority sectors. NCE Standing Selection Committee members are appointed by, and make recommendations to, the NCE Steering Committee.
The NCE Standing Selection Committee reviews Letters of Intent (LOIs) and provides recommendations to the NCE Steering Committee regarding the LOIs recommended to advance to the full application stage of the competition. At the full application stage, an Expert Panel may also be used to assess the excellence of an application. The NCE Standing Selection Committee also reviews the full applications, and considers any additional review reports produced by the Expert Panel. The Committee provides funding recommendations to the NCE Steering Committee.
(Chair) Jane Barratt is the Secretary General of the International Federation on Ageing comprising government and non government members in 62 countries and representing some 50 million older people. She brings to this position over 35 years experience in both public and private sectors in the fields of public health, community and aged care, and ageing and disability. Dr Barratt has strived to strengthen the roles and relationships between government, NGOs, academia and the private sector in order to help shape and influence policy to improve the quality of life of older people. She is a strong contributor to the international dialogue on the intersection of social, cultural and physical environments that impact on the lives of older people. Dr Barratt is a Churchill Fellow, representative of the IFA at the United Nations Economic and Social Council and directly responsible for the formal relations with the Ageing and Life Course Department, World Health Organization. She holds adjunct academic positions, executive positions on ministerial, government and non-government committees and the corporate sectors internationally and has many years of experience in organizational management, staff development and the analysis of operations leading to improvements in policies, programs and client outcomes in the areas of health, ageing and disability.
(Vice-chair) Bill Cheliak is currently the VP of Business Development of Neurodyn, a start-up neurological research company using slowly progressive animal models of neurodegenerative diseases. Dr. Cheliak is also the co-founder of BNC Pharma, a consulting firm that assists companies in the pharma and biotech industries. Dr. Bill Cheliak is the former VP Business Development at Genizon BioSciences and the former VP Business Development and Alliances at Supratek Pharma. Dr. Cheliak has more than 20 years of experience in the biotechnology sector including executive roles at Cobequid Life Sciences and as President of its ProGeneSys division. Dr. Cheliak has held executive positions in the public sector and is currently a member of several senior committees providing advice and recommendations to the Government of Canada on funding of large national science and infrastructure initiatives. Dr. Cheliak has a Ph.D. in population genetics from the University of Alberta.
Klaus Bock has a Master degree in Chemical Engineering from the Technical University of Demark (1968) and a PhD in Organic Chemistry from the same University (1970). He was employed as associate professor in organic chemistry at the Technical University of Denmark from 1970 to 1988. From 1988 he was appointed head and professor of the Chemistry Department of the Carlsberg Laboratory, from 1992 Head of Research at Carlsberg Research Centre on from 2001 to 2007 Executive Vice President for Research of Carlsberg A/S. He has published 260 papers in international journals with referee within the area of analytical and synthetic carbohydrate chemistry with special emphasis of the application of NMR spectroscopy in structural studies of carbohydrate derivatives and their interaction with enzymes. Latest interests focused on protein-carbohydrate interactions, particularly the synthesis and structural analysis of glycopeptides. From 2004 chairman of the Danish National Research Foundation, from 2005 deputy chairman of the Danish National Advanced Technology Foundation and President of the Danish Academy of Technical Sciences 2009-2011.
Bill Borland is presently an Associate with Dillon Consulting Limited in Saint John, New Brunswick. He has held senior environmental management positions with AMEC Environment and Infrastructure, Vice President Canadian Federal Programs (2007 – 2012); J.D. Irving, Limited, Director Environmental Affairs (1989-2007) and NB Power, Manager Environmental Planning (1980-1989). Bill sat on the Boards of the Canadian Water Network (Chair), the Canadian Rivers Institute, NB Research and Productivity Council. He was also a Member of the National Roundtable on the Environment and the Economy (NRTEE) (2001-2005) where he Co-Chaired the Boreal Forest Program and sat on the NRTEE Expert Advisory Committee on Water. He presently sits on the Standing Selection Committee of the Networks of Centres of Excellence and the Boards of ECO Canada (Governance Committee) and Enovex Inc.
Lourdes Casanova is a Senior Lecturer at the Johnson School of Business at Cornell University. Formerly at INSEAD, she specializes in international business with a focus on multinationals in emerging markets. A Fulbright Scholar with a Master’s degree from the University of Southern California and a PhD from the University of Barcelona, she is also a visiting professor at several institutions, such as the Haas School of Business at the University of California-Berkeley, the Judge Business School at University of Cambridge, the Latin American Centre at the University of Oxford, the University of Zurich, and the Universidad Autónoma de Barcelona. She also serves as a consultant of the Inter-American Development Bank, and has taught executive programs at INSEAD for senior managers from multinationals including Telefónica, BBVA and Cemex and the Brazilian Confederation of Industries. Dr. Casanova is a member of Latin America Global Agenda Council of the World Economic Forum, the European Union/Brazil Advisory Committee, the World Investment Network at UNCTAD, and the B20 Task Force on ICT and Innovation in Los Cabos. While at INSEAD, she was responsible for the Goldman Sachs 10,000-women initiative and for co-leading InnovaLatino on Innovation in Latin America. She is a board member of start-up Documenta, and a founding Board Member of the Societé des Amis du Chateau de Fontainebleau.
Gail Charnley is toxicologist specializing in environmental health risk assessment and risk management science and policy. She has over 30 years of experience in the biological, chemical, and social policy aspects of environmental and public health protection. Dr. Charnley focuses on strategic analysis and risk communication of complex scientific and regulatory issues to both nontechnical and scientific audiences. She works primarily on the safety of chemicals in food, environmental media, work environments, and consumer products. She is a lecturer in the Yale School of Public Health and serves on the National Academy of Sciences’ Board on Environmental Studies and Toxicology. She has been executive director of the Presidential/Congressional Commission on Risk Assessment and Risk Management, director of the Toxicology and Risk Assessment Program at the National Academy of Sciences, and President of the international Society for Risk Analysis. She has a PhD in toxicology from MIT and has been an independent consultant since 1999.
Denis Faubert is CEO of the Consortium for Research and Innovation in Aerospace in Québec (CRIAQ) since May 2014 while assuming at the same time the function of CEO of the Canadian Aerospace Research and Innovation Consortium (CARIC) since July 2014. He has previously been the General Manager of the Hydro-Quebec Research Institute (IREQ) for seven years. Within Defence Research and Development Canada, he served as the Director General of the Valcartier Research Centre from 1998 to 2005 and Director General supervising the National Defence Research Program in Ottawa for two years afterwards. He earned an honours Bachelor’s degree in physics from the Royal Military College of Canada and his PhD in Laser Physics from Université Laval. He sits on the Board of Directors of many technical organizations and led a NATO Research Panel on Sensors and Electronics Technology. He has been recognized through many distinctions, including the National Research Council’s prestigious Centennial Scholarship, the Deputy Minister of National Defense’s Innovation Award (2005) and Université Laval’s Faculty of Science Summa-Carrière Award (2008).
David Fung is the chairman and CEO of the ACDEG Group of companies, a global technology integrator, with business partnerships in forest products, clean technologies, chemicals, renewable energy, agrifoods, marine equipment, OEM parts manufacturing and packaging wastes recycling in North America, Europe and Asia. He is a member of the Regulatory Advisory Committee of the Treasury Board of Canada, an “investment champion” for the Canadian Department of Foreign Affairs, Trade and Development, and a member of the Gateway Performance Table of Transport Canada. Dr. Fung is chair of the Chemical Institute of Canada and a strategic advisor of Cycle Capital Management Inc., the largest clean technology venture capital fund in Canada.
Cathy Garner has a life-long dedication to innovation for economic and social improvement and over 20 years of experience in practice. She is founder and current principal of an international consulting network specialising in innovation in cities and university- business partnerships for knowledge exchange. She has worked with clients around the world from Europe to Japan and Australia. She is currently also an Associate of the Council for Industry and Higher Education of the UK; a member of the New Club of Paris and an advisor to the World Capital Institute in Mexico on knowledge-city development. As Chief Executive of Manchester: Knowledge Capital for six years she built a globally recognised partnership for innovation by bridging the boundaries across business, universities and government. Her partnership building skills and style of leadership delivered success by inspiring and supporting innovation across projects and sectors. Manchester achieved global recognition for this effort by being named most admired Knowledge City in 2009. With a background in policy development and research in social housing, regeneration and community development, she has worked in economic development, urban systems, innovation, and knowledge transfer and business entrepreneurship. Her initial academic research career was in school educational performance. In the UK she served on the Strategic Advisory Board for Intellectual Property between 2008 and 2010, was a member of the Cabinet Office Innovators’ Council in 2009. Cathy has served as a non-executive director on number of public and private sector Boards and is a Fellow of the Royal Statistical Society and a Fellow of the Royal Society of Arts. In 2002 Cathy established an international charity to address the health needs of the global poor through creative intellectual property solutions, working with the Rockefeller Foundation, international NGO’s, multinational corporations and universities worldwide. She continues this work in a volunteer capacity. Previously Cathy established and ran the Research and Enterprise Office at the University of Glasgow in Scotland where she led the establishment of the Scottish Institute for Enterprise and was a founder director of the Scottish North American Business Council. She was a member of the Association of University Technology Managers (AUTM) in the USA and served as their inaugural Vice President for International Relations.
Michael Gibbons is Honorary Professorial Fellow in Science and Technology Policy Research with the University of Sussex. Former appointments include Director of the Science Policy Research Unit at Sussex University and Secretary General of the Association of Commonwealth Universities. Prior to these appointments he was Founding Director of the Programme of Policy Research in Engineering Science and Technology at the University of Manchester and Director of Research and Technology Transfer in that University. Dr. Gibbons has an active research interest in science and technology policy generally but has additionally carried out research in the process of technological innovation in industry and the evaluation of research. He is co-author with colleagues of two major books on the nature of contemporary science: New Modes of Knowledge Production and Re-thinking Science, which have arguably set the agenda for much current science policy debate. His work has been vigorously taken up by the South African authorities who have adopted the notion of Mode 2 research as a guiding concept during the current, and ongoing, transformation of the South African higher education system. From 2000 to 2003, he was a member of the UK Economic and Social Research Council and Chair of its Research Priorities Board. From 2004, he was Chair of the Board of Quest University, Canada’s first secular, private, not-for-profit university, based in Squamish, British Columbia. In 2004 he became a Member of the Order of the British Empire (MBE) for services to Higher Education and was awarded the Queen’s Jubilee Medal for excellence in research by the government of Canada.
Greg Hammond has over 35 years of infectious disease experience in the areas of research, clinical care, public health policy and program development. He has served in many senior capacities and leadership roles at provincial and national levels. Dr. Hammond received his training at the universities of McGill, Alberta, Toronto and Manitoba, as well as at the Centres for Disease Control and Prevention in Atlanta, Georgia. He is a Professor in the Departments of Medical Microbiology and Medicine, University of Manitoba. Dr. Hammond has broad experience in public service including: Head, Virus Detection Unit, and Director, Cadham Provincial Public Health Laboratory, Manitoba. He was a member of the National Advisory Committee on Immunization (NACI). He has served as Director of Communicable Disease Control and Director of the Public Health Branch (Manitoba Health). He was a member of the WHO’s Technical Logistics Advisory Committee (TLAC) on immunization. He was the provincial co-chair of the National Immunization Strategy and subsequently the Canadian Immunization Committee. Dr. Hammond is a clinical consultant with the Section of Infectious Diseases, Department of Medicine, Health Sciences Centre and Grace General Hospital. Dr. Hammond is a board member and Chair of the Nominations Committee of the Pan Provincial Vaccine Enterprise (PREVENT), which works with three universities (British Columbia, Dalhousie, and Saskatchewan) to accelerate early candidate vaccine development. He was the Scientific Director of the Alliance Coordinating Office (ACO) of the Canadian HIV Vaccine Initiative (CHVI) in Winnipeg, 2011-2014. He is the Executive Director of the Manitoba Medical Services Foundation (MMSF) of the Manitoba Blue Cross, which provides research and educational grants to new health researchers in Manitoba.
Hugh Ilyine is a biomedical entrepreneur with more than 25 years’ international experience in company leadership in multinational corporations and biotechnology companies, from start-up through to listings on UK and Australian Stock Exchanges. He has covered food and agriculture bio-ingredients, stem cells, biosimilar therapeutics and molecular diagnostic fields from founder through to CEO and company director roles. Hugh has worked previously as a consultant and expert adviser to the Australian, UK and Canadian governments in the fields of stem cell research and regenerative medicine, serving also on the UK and Scottish Stem Cell Networks in advisory roles. He acts currently as an expert reviewer for the UK Technology Strategy Board. He previously enjoyed over 17 years with the Rhône-Poulenc group, including work in the UK, France, Indonesia and Australia. He is a co-founder, CEO and Executive Director of DestiNA Genomics Ltd, a spin-out molecular diagnostic company from the University of Edinburgh; a founder and former CEO of Profactor Pharma Ltd, developing biosimilar therapeutics; and a non-executive director of Regenerys Ltd, a company formed to deliver cell-based product solutions for serious burns, chronic wounds and post-mastectomy breast reconstructions. Hugh has Australian and British dual nationality, is bi-lingual (English and French), and currently lives in Scotland He has a BSc in Applied Science from the University of New South Wales, Sydney, and a marketing degree from Monash University, Melbourne.
John Leggat was the Assistant Deputy Minister (Science & Technology) of the Department of National Defence and the Chief Executive Officer of Defence Research and Development Canada (DRDC). In this capacity, he led DRDC, which provides national leadership in defence science, and furnishes scientific advice and products to the Canadian Forces and the Department of National Defence. During his scientific career, Dr. Leggat has held a number of appointments in defence R&D. As Director General of DRDC’s Ottawa research centre from 1994-1997, he directed a program that addressed radar systems, electronic warfare, communications and space systems. From 1990 to 1994 he was responsible for the technology development program for the Department of National Defence. Prior to this appointment, he spent 14 years at the DRDC Atlantic research centre where he carried out and led research in the area of ship and submarine technology pertaining to noise reduction, hydromechanics, ship structures and materials. Dr. Leggat is a Past President of the International Council of Academies of Engineering and Technological Sciences. He is a Past President of the Canadian Academy of Engineering. He is a member of the Deputy Minister’s Science Advisory Board of the Department of Natural Resources. He is a past President of the Alumni Association of the Royal Military Colleges of Canada.
Robin Mansell is Professor of new media and the internet and former Head of the Department of Media and Communications, London School of Economics and Political Science (2006-09). She served as President of the International Association for Media and Communication Research (2004-08), Scientific Chair of the Euro Communications Policy Research Conference (2008-14) and as Director of Research at the Science Policy Research Unit - SPRU (1999-2000) at the University of Sussex, where she was also Professor of information and communication technology policy (1995-2000. Reader 1988-94). She is interested in the structure of communications and media markets, the sources of regulatory effectiveness and failure, and issues of Internet governance, including intellectual property rights, privacy and security. She is author of many scholarly articles and books, including Imagining the Internet: Communication, Innovation and Governance (Oxford University Press, 2012) and The Handbook of Global Media and Communication (co-edited with M. Raboy, Wiley-Blackwell 2011).
Chris Mason is a Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies, and tissue-engineered products. His multidisciplinary track record spans biopharmaceuticals, medical devices and information technology, in basic science, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business. Current activities include: Chair of the BioIndustry Association (BIA) Regenerative Medicine and Cell Therapy Industry Group, Senior Editor of Regenerative Medicine journal, Trustee of the UK Stem Cell Foundation, Founder and Director of the London Regenerative Medicine Network, President of the Regenerative Medicine Coalition, member of the UK Department of Health Regenerative Medicine Expert Group, member of the UK Clinical Trials, Biologicals & Vaccines Expert Advisory Group of the Commission on Human Medicines, and member of the United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee.
Barbara Mittleman is an internist and rheumatologist with substantial clinical, bench and administrative experience. She earned B.A., and M.D. degrees from the University of Pittsburgh where she also completed residency and fellowship training in Internal Medicine and Rheumatology. She then came to NIH for additional post-doctoral training in cellular immunology, focusing the autoimmunity and pathobiology of systemic lupus erythematosus. In 1995 she was named the inaugural Director of the NIH's Program on Public-Private Partnerships, where she is charged with developing and promulgating policy, brokering interactions among a wide variety of government and non-government partners, and in the development and execution of partnerships which promote the NIH's public health mission. She lectures widely on partnership-related topics and has provided advice and best practices based on NIH's experience to organizations including other Universities, government agencies, foundations and advocacy groups, companies and trade organizations, and others. She also serves on the CIHR Commercialization Advisory Board.
J. Robert S. Prichard is chairman of Torys LLP, a leading international business law firm with offices in Toronto, Calgary, Montréal and New York. He is also chairman of the Bank of Montreal and chair of Metrolinx, the regional transportation agency for the Greater Toronto and Hamilton area. Prior to joining Torys in 2010, Rob had careers as a law professor, academic leader and business leader. He was a professor of law at the University of Toronto from 1976 to 2001, specializing in law and economics and served as dean of the Faculty of Law at the University of Toronto from 1984 to 1990. Rob served as the 13th president of the University of Toronto from 1990 to 2000. Rob’s business experience includes serving from 2002 to 2009 as president and CEO of Torstar Corporation, a leading Canadian media company with newspaper and book publishing businesses. He currently serves as a director of Onex Corporation and George Weston Ltd. (as Lead Director). In the volunteer sector, Rob serves as a trustee of the Hospital for Sick Children and also serves as a member of Ontario’s Economic Advisory Panel. Rob has previously served as Vice Chair of Canada’s Science, Technology and Innovation Council, chair of the Visiting Committee for Harvard Law School and as a member of Canada’s Economic Advisory Council. Rob studied honours economics at Swarthmore College, received his MBA (Dean’s List) in finance and international business from the University of Chicago and earned law degrees from the University of Toronto (Gold Medalist) and Yale University (Viscount Bennett Fellow). Rob has been recognized by appointment as an officer of the Order of Canada, a member of the Order of Ontario and a Fellow of the Royal Society of Canada. He has received honorary degrees from 10 colleges and universities in Canada and the United States, the David Smith Award for contributions to public policy in higher education in Canada, and the Champion of Public Education award from the Learning Partnership.
Paul Root Wolpe, Ph.D. is the Asa Griggs Candler Professor of Bioethics, Raymond Schinazi Distinguished Research Professor of Jewish Bioethics, Professor of Medicine, Pediatrics, Psychiatry, Neuroscience and Biological Behavior, and Sociology, and the Director of the Center for Ethics at Emory University. Dr. Wolpe also serves as the Senior Bioethicist at the National Aeronautics and Space Administration (NASA). He is an editor of the American Journal of Bioethics (AJOB) and Editor-in-Chief of AJOB-Neuroscience, and sits on the editorial boards of over a dozen professional journals in medicine and ethics. Dr Wolpe is a past President of the American Society for Bioethics and Humanities, a Fellow of the Hastings Center, and a Fellow of the College of Physicians of Philadelphia, the country’s oldest medical society. Dr. Wolpe publishes in sociology, medicine, and bioethics, and has contributed to a variety of encyclopedias on bioethical issues. His work focuses on the social, religious, and ideological impact of technology on the human condition. Considered one of the founders of the field of neuroethics, which examines the ethical implications of neuroscience, he also writes about other emerging technologies, such as genetic engineering and functional prosthetics. His teaching and publications range across multiple fields of bioethics and sociology, including death and dying, genetics and eugenics, clinical care, sexuality and gender, mental health and illness, alternative medicine, and bioethics in extreme environments such as space.